126 results about "Herpes simplex virus" patented technology

The invention discloses a reagent and a method for detecting berberine-resistant viruses. The reagent provided by the invention comprises an antibody or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR1-3 and / or a light chain complementarity determining region LCDR1-3, the heavy chain complementarity determining region HCDR1-3 has a sequence as shown in SEQ ID NO.5-7, and the light chain complementarity determining region LCDR1-3 has a sequence as shown in SEQ ID NO.8-10. The reagent can be used for detecting the berberine-resistant herpes simplex virus type 1, so that the treatment effect can be evaluated in advance before berberine is applied for treatment.

The present invention discloses a biomarker for predicting the efficacy of oncolytic virus in treating malignant tumors and its application. The biomarker includes SH3BP2, the oncolytic virus is oncolytic herpes simplex virus, and the malignant tumor is glioma. Before treating malignant glioma with oncolytic virus, the expression level of SH3BP2 in tumor tissues before treatment is detected to predict the therapeutic effect of oncolytic virus on malignant glioma.

The invention relates to the field of medicinal chemistry, and particularly discloses purine compounds as well as a preparation method and application thereof. The purine compound provided by the invention is a compound as shown in a formula (I) or pharmaceutically acceptable salt thereof: # imgabs0 #. The purine compound disclosed by the invention is designed based on a novel purine skeleton structure, and the anti-herpes simplex virus type 1 (HSV-1) activity of the purine compound is verified through an in-vitro antiviral experiment. Experimental data show that the HSV-1 median inhibitory concentration (EC50) of the series of compounds to HSV-1 is obviously superior to that of a clinical first-line drug acyclovir, and the series of compounds show better virus inhibition efficiency on the premise of keeping a similar selectivity index (SI = CC50 / EC50). The technical scheme breaks through the molecular framework limitation of the existing anti-HSV-1 drugs (such as acyclovir, famciclovir and the like), and has good clinical transformation value.

A method of treating spasm in a subject is provided. The method comprises directly administering a herpes simplex virus type 1 (HSV-1) vector carrying a glutamate decarboxylase (GAD) gene (preferably GAD67) to one or more epithelial regions of the subject.

Herpesviridae glycoprotein B (gB) polypeptides comprising a modified ectodomain is stabilized in the prefusion state, enabling development of inhibitors and vaccines directed against these viral pathogens. Modifications to DI, DII, and DV subdomains are important to stabilization of gB in the prefusion state, and additional modifications result in a further improved stabilization of gB in the prefusion state. The gB can be derived from an Epstein Barr Virus (EBV), a Human Cytomegalovirus (CMV), a Human Herpesvirus 6 (HHV6), a Herpes Simplex Virus 1 (HSV1), or a Varicella Zoster Virus (VZV). Polypeptides, nucleic acid constructs, compositions, and methods of using same to elicit an immune response are described.

The invention provides a recombinant herpes simplex virus and a herpes simplex virus modification method. The herpes simplex virus modification method comprises the step of replacing an ICP4 protein coding gene in a herpes simplex virus genome containing an infected cell protein 4 (ICP4) gene with an hTERTp-fluorescent protein expression cassette. The expression cassette comprises an hTERTp promoter and a fluorescent protein coding sequence controlled by the hTERTp promoter, and the transcription direction is opposite to that of an ICP4 promoter in a genome. The hTERTp-fluorescent protein expression cassette in the recombinant virus obtained by the method disclosed by the invention can be normally expressed in response to telomerase activity. Therefore, the recombinant virus is capable of expressing a fluorescent protein, such as mBaoJin, in a cell having human telomerase activity. Cells infected by the virus can be identified through fluorescence signals, and the higher the telomerase activity is, the stronger the fluorescence intensity is. The virus has wide application value in research of tumor action mechanisms and stem cell action mechanisms, health assessment, screening of tumor drugs, research and development of diagnostic reagents and establishment of animal models.

Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer / promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).

The present invention relates to a liquid composition characterized in that it comprises: a live attenuated herpes simplex virus 1 (HSV-1); 17.5 mg / mL to 22.5 mg / mL of recombinant human serum albumin (rHSA); less than 5 mg / mL of sucrose; 26 mg / mL to 32 mg / mL of sorbitol; 13.5 mg / mL to 16 mg / mL of potassium phosphate and 3 mg / mL to 7 mg / mL of sodium chloride, wherein the liquid composition comprises no more than 0.01 mM of any of lactose, gelatin, antibiotic and free amino acids.

The invention discloses a function and an application of a fish LIM and SH3 structural domain protein 1 (LASP1) gene in fish antiviral immune regulation, and particularly discloses a molecular mechanism and an application value of the LASP1 as an immune negative regulation factor in carassius auratus herpesvirus (CaHV) infection. Experiments prove that fish LASP1 has the function of remarkably inhibiting immune regulation generated by host interferon and can promote CaHV proliferation for the first time, and knock-down of the gene can effectively enhance host antiviral response and inhibit CaHV infection. Therefore, the lasp1 gene can be used as a new target for preventing and treating CaHV infection, is used for preparing a preparation for preventing or treating CaHV infection, or is used for gene editing of a cell model for preventing CaHV infection or a new crucian carp variety.

Provided herein are Vero cell lines that stably express Herpes Simplex Virus (HSV) ICP0 protein. These cells have the same morphology of Vero cells, exhibit stable expression of HSV ICP0 protein, and also efficiently complement replication of HSV ICP0 deficient virus for greater than 20, 30, or even 40 cell passages.

The technical problem is to develop a novel armed oncolytic herpes simplex virus (HSV) with G47 delta as a skeleton. Provided is a pharmaceutical composition containing an IL-12 expression-type genetically recombinant herpes simplex virus (HSV) that has a gene encoding a fusion polypeptide in which a 35 kDa light chain (p35) and a 40 kDa heavy chain (p40) of interleukin 12 (IL-12) are linked by two or more elastin motifs, and that has the following characteristics (a) to (c). (a) the ICP6 gene is deleted or inactivated; (b) deletion or inactivation of the gamma34.5 gene; and (c) the alpha 47 gene is deleted or inactivated.

Disclosed is a replication incompetent HSV-1 viral vaccine comprising a modified genome of HSV-1 and at least one antigen. The modification comprises a deletion of internal repeats, an inactivating mutation in ICP47 and an inactivating mutation in the other copy of ICP4. A first antigen of the at least one antigen is driven by a promoter of an immediate early gene, such as ICP4. In a specific example, the HSV-1 viral vaccine expresses antigens from SARS-Cov, SARS-Cov-2 and variants thereof and is used for inducing immune responses against sarbecoviruses in a subject to which the vaccine is administered.

Provided herein are non-natural herpes simplex virus (“HSV”) vectors and one or more polynucleotides encoding IL-21 or a biologically active fragment of IL-21 for use in the treatment of cancer.

The invention belongs to the field of preparation of high-antibacterial carbon dots, and discloses a high-antibacterial carbon dot, a preparation process and application of the high-antibacterial carbon dot in vaginal gel. The prepared carbon dots are prepared by adopting physical shearing and ultrasonic synergistic pretreatment, then cooperating with microwave gradient energy crushing and stripping, and then performing centrifugation, dialysis purification and vacuum freeze drying, the damage of oxidation or acid treatment to a graphite structure is avoided in the whole process, and the carbon dots have excellent antibacterial and antiviral performance, can effectively inactivate various pathogenic microorganisms, and have good application prospects. Comprise herpes simplex virus, human papilloma virus HPV16, staphylococcus aureus, candida albicans and the like. The invention also optimizes application conditions, is suitable for developing efficient and safe vagina antibacterial gel products, and provides an innovative solution for preventing and treating gynecological infection.

The virus of the present disclosure is a multiple mutant virus in which two or more genes of herpes simplex virus type 2 (HSV-2) are altered and the alteration of the genes is impaired or reduced in gene function.

The present application relates to a virus purification method. The present application relates to a method for purification of herpes simplex virus (HSV-1). The present application also relates to HSV-1 purified according to the method. In particular, the method does not comprise an ultrafiltration concentration step. In particular, the method has a high virus titer yield and a high impurity removal rate.

The invention relates to medicine, and more particularly to therapy, and can be used for treating chronic recurrent infection caused by type 1 and 2 herpes simplex viruses (HSV). According to the proposed method, no sooner than 10-14 days after the subsidence of a repeat flare-up, an extract of aspen bark harvested in the autumn-winter period is administered as an interferon inducer in an amount of 3.7 ml 3 times per day after food and washed down with water at room temperature, the full course of treatment lasting 90 days. The invention provides increased therapeutic efficacy and a reduced frequency and duration of recurrent infection by inducing a high level of (alpha and gamma) interferons in HSV-1 and HSV-2 patients.

The invention discloses application of a gp130 inhibitor in preparation of a medicine for treating virus infection, and relates to the technical field of medicines. Experiments prove that combination of IL-6 family cell factors and a gp130 receptor is inhibited, so that downward signal transmission of a JAK2 / STAT3 signal channel triggered by the IL-6 family cell factors is inhibited, the purposes of inhibiting cell fusion induced by SARS-CoV-2 spike protein and further influencing replication and propagation of SARS-CoV-2 are achieved, and a small-molecule inhibitor SC144 is an inhibitor of gp130, has a remarkable effect of inhibiting SARS-CoV-2 virus replication and has a good application prospect. Meanwhile, the traditional Chinese medicine composition also has a remarkable effect of inhibiting replication of viruses such as human immunodeficiency virus, herpes simplex virus and respiratory syncytial virus.

The invention discloses an application of an attenuated herpes simplex virus in preparation of a neural circuit reverse tracing tool virus, and the attenuated herpes simplex virus is prepared based on a targeting vector. The targeting vector is a vector in which a complete fluorescent protein gene or other exogenous target gene expression cassettes are inserted between the upstream and downstream homologous arms of the neurovirulence factor gamma 34.5 gene of the vector pH129 delta RL1. It is found for the first time that the ltHSV-hUbC-tdT-WPRE virus can be used for neural circuit reverse tracing, efficient axonal ending infection can be carried out so as to reversely mark an upstream regulation and control brain region of a target brain region, and marking as long as two months only observes cellular signals in the upstream brain region which can be directly projected to the target brain region; and the system does not show cis-synaptic propagation, and can be used as a novel tracing virus system with relatively rigorous reverse marking capability and wider-spectrum neurotropism.

An HSV vector with ICP27 under control of CXCR4 promoter and ICP34.5 under control of miRNA-124 / 143, wherein the vector has a deletion of one RL and one RS region of the viral genome. Within optional embodiments the mutation is a deletion containing the second copy of the ICP34.5 gene. These constructs provide increased safety without sacrificing efficacy. The HSV vector also incorporates a virus-expressed cytokine cassette encoding IL-12, IL-15 / IL-15RA under the control of CMV promoter.

The present invention provides a herpes simplex virus targeting IL13RA2 that cues an anti-IL13RA2 antibody, or an antigen-binding fragment thereof, to the surface of the virus. Also provided is an anti-IL13RA2 antibody or an antigen-binding fragment thereof that can specifically recognize tumor cells.

The invention discloses a sulfonated calix [4] arene derivative and application thereof in resisting I-type herpes simplex virus (HSV-1), and belongs to the field of biological medicine. The invention relates to a sulfonated calix [4] arene derivative, which has a structural general formula as follows: R is equal to The preparation method comprises the following steps: adding sodium hydride into a raw material C4A in a polar aprotic solvent to react with alkyl halide to obtain a C4AH or C4AD intermediate; and reacting the intermediate with chlorosulfonic acid in a chlorine-containing solvent, and adding an alkaline alcohol solvent for treatment to obtain the sulfonated calix [4] arene derivative. The calix [4] arene derivative has a relatively good inhibition rate on expression of HSV-1gB and gD genes, and does not have obvious cytotoxicity.

The present invention discloses a 3-hydroxypyridone-5-amide compound and its medical use. Experiments have shown that the 3-hydroxypyridone-5-amide derivative can effectively inhibit the replication of herpes simplex virus in Vero cell lines, and some compounds have inhibitory activity against herpes simplex virus comparable to that of acyclovir. At the same time, the 3-hydroxypyridone-5-amide compound has a high inhibitory effect on acyclovir-resistant strains (HSV-1tkLTRZ1), can overcome the resistance of herpes simplex virus to the first-line drug acyclovir, has anti-herpes simplex virus effect, and can be used to prepare active drugs against herpes simplex virus. The general structural formula is as follows (I): #imgabs0#

Provided herein are compositions and methods useful for the detection of herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), and varicella zoster virus (VZV). In particular, provided herein are compositions, methods, systems, kits, reagents and reaction mixtures related thereto for nucleic acid amplification and detection procedures for detecting HSV-1, HSV-2, and VZV in a sample.

Described herein are compositions and methods for reducing or eliminating latent herpes simplex virus type 2 (HSV-2) in HSV-2 infected cells, or for reducing or eliminating latent HSV-2 reactivation in HSV-2 infected cells, thereby providing viable therapeutic methods for latent HSV-2 infection. The compositions comprise a plurality of viral vectors, where the viral vectors comprise a sequence encoding a HSV-2 specific megasuclease. The method comprises delivering a plurality of one or more viral vectors to the HSV-2 infected cell, where each of the one or more viral vectors comprises a sequence encoding an HSV-2 specific megasuclease.

The present invention provides a method for treating spasticity in a subject. The method includes direct administration of a herpes simplex virus 1 (HSV-1) vector harboring a glutamic acid decarboxylase (GAD) gene (preferably. GAD67) into one or more dermatomes of the subject.

The disclosure provides a non-natural herpes simplex virus (“HSV”), compositions comprising, or alternatively consisting essentially of, or yet further consisting of the HSV, and methods of producing the HSV, or infecting a cell with the HSV. Also provided herein are methods of treating cancer or inhibiting the growth or metastasis of cancer cell in a subject in need thereof.

The present invention provides a method for efficiently delivering a transgene to the brain of a subject. The method includes intrathecal administration or one or more injections into the striatum of a replication defective herpes simplex virus (rdHSV) vector comprising an inactivating mutation of one copy of infected cell protein 0 (ICP0) HSV gene; and wherein the rdHSV-1 vector expresses a functional ICP0 protein from the other copy of the ICP0 gene.

The virus disclosed by the invention is a multi-mutant virus, and the multi-mutant virus is a multi-mutant virus in which more than two genes of herpes simplex virus type 1 (HSV-1) are changed, and the change of the genes is that gene functions are deleted or reduced.

The invention discloses a kit for detecting berberine-resistant viruses and application of the kit. The kit provided by the invention comprises an antibody or an antigen binding fragment thereof, a buffer agent and a signal generation system, the antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR1-3 and a light chain complementarity determining region LCDR1-3, the sequences of the heavy chain complementarity determining region HCDR1-3 are respectively as shown in SEQ ID NO.5-7, the sequences of the light chain complementarity determining region LCDR1-3 are respectively as shown in SEQ ID NO.8-10, and the signal generation system comprises a buffer agent and a signal generation system. Or the sequences of the heavy chain complementarity determining region HCDR1-3 are respectively shown as SEQ ID NO.15-17, and the sequences of the light chain complementarity determining region LCDR1-3 are respectively shown as SEQ ID NO.18-20. The kit can be used for detecting the berberine-resistant herpes simplex virus type 1, so that the treatment effect can be evaluated in advance before berberine is applied for treatment.